Закон Пермского края от 25.12.2014 № 427-ПК

¦     ¦инструментальных     ¦                ¦                          ¦               ¦холангиографию)          ¦              ¦

¦     ¦исследований         ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦(включая             ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦магнитно-резонансную ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦холангиографию)      ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦                     ¦                +--------------------------+               ¦                         ¦              ¦

¦     ¦                     ¦                ¦хронический аутоиммунный  ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦гепатит в сочетании с     ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦первичным билиарным       ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦циррозом печени           ¦               ¦                         ¦              ¦

¦     ¦                     ¦                +--------------------------+               ¦                         ¦              ¦

¦     ¦                     ¦                ¦хронический аутоиммунный  ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦гепатит в сочетании с     ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦хроническим вирусным      ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦гепатитом C               ¦               ¦                         ¦              ¦

¦     ¦                     ¦                +--------------------------+               ¦                         ¦              ¦

¦     ¦                     ¦                ¦хронический аутоиммунный  ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦гепатит в сочетании с     ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦хроническим вирусным      ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦гепатитом E               ¦               ¦                         ¦              ¦

+-----+---------------------+----------------+--------------------------+---------------+-------------------------+--------------+

¦                                                           ГЕМАТОЛОГИЯ                                                          ¦

+-----T---------------------T----------------T--------------------------T---------------T-------------------------T--------------+

¦  5  ¦Комплексное лечение, ¦  D69.1, D82.0, ¦патология гемостаза,      ¦терапевтическое¦прокоагулянтная терапия  ¦    119808    ¦

¦     ¦включая              ¦ D69.5, D58, D59¦резистентная к            ¦лечение        ¦с использованием         ¦              ¦

¦     ¦полихимиотерапию,    ¦                ¦стандартной терапии, и    ¦               ¦рекомбинантных           ¦              ¦

¦     ¦иммунотерапию,       ¦                ¦(или) с течением,         ¦               ¦препаратов факторов      ¦              ¦

¦     ¦трансфузионную       ¦                ¦осложненным угрожаемыми   ¦               ¦свертывания, массивные   ¦              ¦

¦     ¦терапию препаратами  ¦                ¦геморрагическими          ¦               ¦трансфузии компонентов   ¦              ¦

¦     ¦крови и плазмы,      ¦                ¦явлениями. Гемолитическая ¦               ¦донорской крови          ¦              ¦

¦     ¦методы               ¦                ¦анемия, резистентная к    ¦               ¦                         ¦              ¦

¦     ¦экстракорпорального  ¦                ¦стандартной терапии, или  ¦               ¦                         ¦              ¦

¦     ¦воздействия на       ¦                ¦с течением, осложненным   ¦               ¦                         ¦              ¦

¦     ¦кровь, дистанционную ¦                ¦тромбозами и другими      ¦               ¦                         ¦              ¦

¦     ¦лучевую терапию,     ¦                ¦жизнеугрожающими          ¦               ¦                         ¦              ¦

¦     ¦хирургические методы ¦                ¦синдромами                ¦               ¦                         ¦              ¦

¦     ¦лечения при          ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦апластических        ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦анемиях,             ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦апластических,       ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦цитопенических и     ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦цитолитических       ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦синдромах,           ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦агранулоцитозе,      ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦нарушениях           ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦плазменного и        ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦тромбоцитарного      ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦гемостаза, острой    ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦лучевой болезни      ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+              ¦

¦     ¦                     ¦      D69.3     ¦патология гемостаза,      ¦терапевтическое¦терапевтическое лечение, ¦              ¦

¦     ¦                     ¦                ¦резистентная к            ¦лечение        ¦включающее               ¦              ¦

¦     ¦                     ¦                ¦стандартной терапии, и    ¦               ¦иммуносупрессивную       ¦              ¦

¦     ¦                     ¦                ¦(или) с течением,         ¦               ¦терапию с использованием ¦              ¦

¦     ¦                     ¦                ¦осложненным угрожаемыми   ¦               ¦моноклональных антител,  ¦              ¦

¦     ¦                     ¦                ¦геморрагическими явлениями¦               ¦иммуномодулирующую       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦терапию с помощью        ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦рекомбинантных           ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦препаратов тромбопоэтина ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+              ¦

¦     ¦                     ¦      D69.0     ¦патология гемостаза,      ¦комбинированное¦комплексное              ¦              ¦

¦     ¦                     ¦                ¦резистентная к            ¦лечение        ¦консервативное и         ¦              ¦

¦     ¦                     ¦                ¦стандартной терапии, и    ¦               ¦хирургическое лечение, в ¦              ¦

¦     ¦                     ¦                ¦(или) с течением,         ¦               ¦том числе                ¦              ¦

¦     ¦                     ¦                ¦осложненным тромбозами    ¦               ¦антикоагулянтная,        ¦              ¦

¦     ¦                     ¦                ¦или тромбоэмболиями       ¦               ¦антиагрегантная и        ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦фибринолитическая        ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦терапия, ферментотерапия ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦антипротеазными          ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦лекарственными           ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦препаратами,             ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦глюкокортикостероидная   ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦терапия и пульс-терапия  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦высокодозная,            ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦комплексная              ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦иммуносупрессивная       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦терапия с использованием ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦моноклональных антител,  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦заместительная терапия   ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦препаратами крови и      ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦плазмы, плазмаферез      ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+--------------+

¦     ¦                     ¦      M31.1     ¦патология гемостаза,      ¦комбинированное¦комплексная              ¦              ¦

¦     ¦                     ¦                ¦резистентная к            ¦лечение        ¦иммуносуппрессивная      ¦              ¦

¦     ¦                     ¦                ¦стандартной терапии, и    ¦               ¦терапия с использованием ¦              ¦

¦     ¦                     ¦                ¦(или) с течением,         ¦               ¦моноклональных антител,  ¦              ¦

¦     ¦                     ¦                ¦осложненным тромбозами    ¦               ¦высоких доз              ¦              ¦

¦     ¦                     ¦                ¦или тромбоэмболиями,      ¦               ¦глюкокортикостероидных   ¦              ¦

¦     ¦                     ¦                ¦анемическим,              ¦               ¦препаратов. Массивные    ¦              ¦

¦     ¦                     ¦                ¦тромбоцитопеническим      ¦               ¦плазмообмены.            ¦              ¦

¦     ¦                     ¦                ¦синдромом                 ¦               ¦Диагностический          ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦мониторинг: определение  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦мультимерности фактора   ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦Виллебранда,             ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦концентрации протеазы,   ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦расщепляющей фактор      ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦Виллебранда              ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+--------------+

¦     ¦                     ¦      D68.8     ¦патология гемостаза, в    ¦комбинированное¦комплексное              ¦              ¦

¦     ¦                     ¦                ¦том числе с               ¦лечение        ¦консервативное и         ¦              ¦

¦     ¦                     ¦                ¦катастрофическим          ¦               ¦хирургическое лечение, в ¦              ¦

¦     ¦                     ¦                ¦антифосфолипидным         ¦               ¦том числе эфферентные    ¦              ¦

¦     ¦                     ¦                ¦синдромом, резистентным к ¦               ¦методы лечения,          ¦              ¦

¦     ¦                     ¦                ¦стандартной терапии, и    ¦               ¦антикоагулянтная и       ¦              ¦

¦     ¦                     ¦                ¦(или) с течением,         ¦               ¦антиагрегантная терапия, ¦              ¦

¦     ¦                     ¦                ¦осложненным тромбозами    ¦               ¦иммуносупрессивная       ¦              ¦

¦     ¦                     ¦                ¦или тромбоэмболиями       ¦               ¦терапия с использованием ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦моноклональных антител,  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦массивный обменный       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦плазмаферез              ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+--------------+

¦     ¦                     ¦  E83.1, Е83.2  ¦цитопенический синдром,   ¦комбинированное¦комплексное              ¦              ¦

¦     ¦                     ¦                ¦перегрузка железом,       ¦лечение        ¦консервативное и         ¦              ¦

¦     ¦                     ¦                ¦цинком и медью            ¦               ¦хирургическое лечение,   ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦включающее эфферентные и ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦афферентные методы       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦лечения, противовирусную ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦терапию, метаболическую  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦терапию, хелаторную      ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦терапию,                 ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦антикоагулянтную и       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦дезагрегантную терапию,  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦заместительную терапию   ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦компонентами крови и     ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦плазмы                   ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+--------------+

¦     ¦                     ¦    D59, D56,   ¦гемолитический криз при   ¦комбинированное¦комплексное              ¦              ¦

¦     ¦                     ¦   D57.0, D58   ¦гемолитических анемиях    ¦лечение        ¦консервативное и         ¦              ¦

¦     ¦                     ¦                ¦различного генеза, в том  ¦               ¦хирургическое лечение, в ¦              ¦

¦     ¦                     ¦                ¦числе аутоиммунного, при  ¦               ¦том числе высокодозная   ¦              ¦

¦     ¦                     ¦                ¦пароксизмальной ночной    ¦               ¦пульс-терапия            ¦              ¦

¦     ¦                     ¦                ¦гемоглобинурии            ¦               ¦стероидными гормонами,   ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦иммуномодулирующая       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦терапия,                 ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦иммуносупрессивная       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦терапия с использованием ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦моноклональных антител,  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦использование            ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦рекомбинантных           ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦колониестимулирующих     ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦факторов роста           ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+--------------+

¦     ¦                     ¦       D70      ¦агранулоцитоз с           ¦терапевтическое¦консервативное лечение,  ¦              ¦

¦     ¦                     ¦                ¦показателями              ¦лечение        ¦в том числе              ¦              ¦

¦     ¦                     ¦                ¦нейтрофильных лейкоцитов  ¦               ¦антибактериальная,       ¦              ¦

¦     ¦                     ¦                ¦крови 0,5 x 109/л и ниже  ¦               ¦противовирусная,         ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦противогрибковая         ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦терапия, использование   ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦рекомбинантных           ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦колониестимулирующих     ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦факторов роста           ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+--------------+

¦     ¦                     ¦       D60      ¦парциальная               ¦терапевтическое¦комплексное              ¦              ¦

¦     ¦                     ¦                ¦красноклеточная аплазия,  ¦лечение        ¦консервативное лечение,  ¦              ¦

¦     ¦                     ¦                ¦резистентная к терапии    ¦               ¦в том числе программная  ¦              ¦

¦     ¦                     ¦                ¦глюкокортикоидными        ¦               ¦иммуносупрессивная       ¦              ¦

¦     ¦                     ¦                ¦гормонами,                ¦               ¦терапия, заместительная  ¦              ¦

¦     ¦                     ¦                ¦сопровождающаяся          ¦               ¦терапия компонентами     ¦              ¦

¦     ¦                     ¦                ¦гемосидерозом (кроме      ¦               ¦донорской крови,         ¦              ¦

¦     ¦                     ¦                ¦пациентов, перенесших     ¦               ¦противовирусная терапия, ¦              ¦

¦     ¦                     ¦                ¦трансплантацию костного   ¦               ¦хелаторная терапия       ¦              ¦

¦     ¦                     ¦                ¦мозга, пациентов с        ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦почечным трансплантатом)  ¦               ¦                         ¦              ¦

¦     +---------------------+----------------+--------------------------+---------------+-------------------------+--------------+

¦     ¦Интенсивная терапия, ¦  E80.0, E80.1, ¦прогрессирующее течение   ¦терапевтическое¦комплексная              ¦              ¦

¦     ¦включающая методы    ¦      E80.2     ¦острых печеночных         ¦лечение        ¦консервативная терапия,  ¦              ¦

¦     ¦экстракорпорального  ¦                ¦порфирий, осложненное     ¦               ¦включая эфферентные и    ¦              ¦

¦     ¦воздействия на кровь ¦                ¦развитием бульбарного     ¦               ¦афференные методы        ¦              ¦

¦     ¦у больных с          ¦                ¦синдрома, апноэ,          ¦               ¦лечения, хирургические   ¦              ¦

¦     ¦порфириями           ¦                ¦нарушениями функций       ¦               ¦вмешательства,           ¦              ¦

¦     ¦                     ¦                ¦тазовых органов,          ¦               ¦подавление избыточного   ¦              ¦

¦     ¦                     ¦                ¦торпидное к стандартной   ¦               ¦синтеза продуктов        ¦              ¦

¦     ¦                     ¦                ¦терапии, с тяжелой        ¦               ¦порфиринового            ¦              ¦

¦     ¦                     ¦                ¦фотосенсибилизацией и     ¦               ¦метаболизма инфузионной  ¦              ¦

¦     ¦                     ¦                ¦обширными поражениями     ¦               ¦терапией, интенсивная    ¦              ¦

¦     ¦                     ¦                ¦кожных покровов, с        ¦               ¦терапия, включая методы  ¦              ¦

¦     ¦                     ¦                ¦явлениями системного      ¦               ¦протезирования функции   ¦              ¦

¦     ¦                     ¦                ¦гемохроматоза/гемосидероза¦               ¦дыхания и почечной       ¦              ¦

¦     ¦                     ¦                ¦тканей -                  ¦               ¦функции,                 ¦              ¦

¦     ¦                     ¦                ¦эритропоэтической         ¦               ¦молекулярно-генетическое ¦              ¦

¦     ¦                     ¦                ¦порфирией, поздней кожной ¦               ¦исследование больных с   ¦              ¦

¦     ¦                     ¦                ¦порфирией                 ¦               ¦латентным течением       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦острой порфирии с целью  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦предотвращения развития  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦кризового течения,       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦хелаторная терапия       ¦              ¦

+-----+---------------------+----------------+--------------------------+---------------+-------------------------+--------------+

¦                                                       ДЕРМАТОВЕНЕРОЛОГИЯ                                                       ¦

+-----T---------------------T----------------T--------------------------T---------------T-------------------------T--------------+

¦  6  ¦Комплексное лечение  ¦      L40.0     ¦тяжелые распространенные  ¦терапевтическое¦лечение с применением    ¦     80713    ¦

¦     ¦больных тяжелыми     ¦                ¦формы псориаза без        ¦лечение        ¦узкополосной             ¦              ¦

¦     ¦распространенными    ¦                ¦поражения суставов при    ¦               ¦средневолновой           ¦              ¦

¦     ¦формами псориаза,    ¦                ¦отсутствии эффективности  ¦               ¦фототерапии, в том числе ¦              ¦

¦     ¦атопического         ¦                ¦ранее проводимых методов  ¦               ¦локальной,               ¦              ¦

¦     ¦дерматита, истинной  ¦                ¦системного и              ¦               ¦комбинированной          ¦              ¦

¦     ¦пузырчатки,          ¦                ¦физиотерапевтического     ¦               ¦локальной и общей        ¦              ¦

¦     ¦локализованной       ¦                ¦лечения                   ¦               ¦фотохимиотерапии, общей  ¦              ¦

¦     ¦склеродермии,        ¦                ¦                          ¦               ¦бальнеофотохимиотерапии, ¦              ¦

¦     ¦лучевого дерматита   ¦                ¦                          ¦               ¦плазмафереза в сочетании ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦с цитостатическими и     ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦иммуносупрессивными      ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦лекарственными           ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦препаратами и            ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦синтетическими           ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦производными витамина A  ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+              ¦

¦     ¦                     ¦  L40.1, L40.3  ¦пустулезные формы         ¦терапевтическое¦лечение с применением    ¦              ¦

¦     ¦                     ¦                ¦псориаза при отсутствии   ¦лечение        ¦цитостатических и        ¦              ¦

¦     ¦                     ¦                ¦эффективности ранее       ¦               ¦иммуносупрессивных       ¦              ¦

¦     ¦                     ¦                ¦проводимых методов        ¦               ¦лекарственных            ¦              ¦

¦     ¦                     ¦                ¦системного и              ¦               ¦препаратов,              ¦              ¦

¦     ¦                     ¦                ¦физиотерапевтического     ¦               ¦синтетических            ¦              ¦

¦     ¦                     ¦                ¦лечения                   ¦               ¦производных витамина A в ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦сочетании с применением  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦плазмафереза             ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+              ¦

¦     ¦                     ¦      L40.5     ¦тяжелые распространенные  ¦терапевтическое¦лечение с применением    ¦              ¦

¦     ¦                     ¦                ¦формы псориаза            ¦лечение        ¦низкоинтенсивной         ¦              ¦

¦     ¦                     ¦                ¦артропатического при      ¦               ¦лазерной терапии,        ¦              ¦

¦     ¦                     ¦                ¦отсутствии эффективности  ¦               ¦узкополосной             ¦              ¦

¦     ¦                     ¦                ¦ранее проводимых методов  ¦               ¦средневолновой           ¦              ¦

¦     ¦                     ¦                ¦системного и              ¦               ¦фототерапии, в том числе ¦              ¦

¦     ¦                     ¦                ¦физиотерапевтического     ¦               ¦локальной,               ¦              ¦

¦     ¦                     ¦                ¦лечения                   ¦               ¦комбинированной          ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦локальной и общей        ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦фотохимиотерапии, общей  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦бальнеофотохимиотерапии, ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦в сочетании с            ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦цитостатическими и       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦иммуносупрессивными      ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦лекарственными           ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦препаратами и            ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦синтетическими           ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦производными витамина A  ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+              ¦

¦     ¦                     ¦       L20      ¦тяжелые распространенные  ¦терапевтическое¦лечение с применением    ¦              ¦

¦     ¦                     ¦                ¦формы атопического        ¦лечение        ¦узкополосной             ¦              ¦

¦     ¦                     ¦                ¦дерматита при отсутствии  ¦               ¦средневолновой, дальней  ¦              ¦

¦     ¦                     ¦                ¦эффективности ранее       ¦               ¦длинноволновой           ¦              ¦

¦     ¦                     ¦                ¦проводимых методов        ¦               ¦фототерапии в сочетании  ¦              ¦

¦     ¦                     ¦                ¦системного и              ¦               ¦с антибактериальными,    ¦              ¦

¦     ¦                     ¦                ¦физиотерапевтического     ¦               ¦иммуносупрессивными      ¦              ¦

¦     ¦                     ¦                ¦лечения                   ¦               ¦лекарственными           ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦препаратами и            ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦плазмаферезом            ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+              ¦

¦     ¦                     ¦  L10.0, L10.1, ¦истинная                  ¦терапевтическое¦лечение с применением    ¦              ¦

¦     ¦                     ¦  L10.2, L10.4  ¦(акантолитическая)        ¦лечение        ¦системных                ¦              ¦

¦     ¦                     ¦                ¦пузырчатка                ¦               ¦глюкокортикостероидных,  ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦цитостатических,         ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦иммуносупрессивных,      ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦антибактериальных        ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦лекарственных препаратов ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+              ¦

¦     ¦                     ¦      L94.0     ¦локализованная            ¦терапевтическое¦лечение с применением    ¦              ¦

¦     ¦                     ¦                ¦склеродермия при          ¦лечение        ¦дальней длинноволновой   ¦              ¦

¦     ¦                     ¦                ¦отсутствии эффективности  ¦               ¦фототерапии в сочетании  ¦              ¦

¦     ¦                     ¦                ¦ранее проводимых методов  ¦               ¦с антибактериальными,    ¦              ¦

¦     ¦                     ¦                ¦системного и              ¦               ¦глюкокортикостероидными, ¦              ¦

¦     ¦                     ¦                ¦физиотерапевтического     ¦               ¦сосудистыми и            ¦              ¦

¦     ¦                     ¦                ¦лечения                   ¦               ¦ферментными              ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦лекарственными           ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦препаратами              ¦              ¦

¦     +---------------------+----------------+--------------------------+---------------+-------------------------+--------------+

¦     ¦Лечение тяжелых,     ¦      L40.0     ¦тяжелые распространенные  ¦терапевтическое¦лечение с применением    ¦              ¦

¦     ¦резистентных форм    ¦                ¦формы псориаза,           ¦лечение        ¦генно-инженерных         ¦              ¦

¦     ¦псориаза, включая    ¦                ¦резистентные к другим     ¦               ¦биологических            ¦              ¦

¦     ¦псориатический       ¦                ¦видам системной терапии   ¦               ¦лекарственных препаратов ¦              ¦

¦     ¦артрит, с            ¦                ¦                          ¦               ¦в сочетании с            ¦              ¦

¦     ¦применением          ¦                ¦                          ¦               ¦иммуносупрессивными      ¦              ¦

¦     ¦генно-инженерных     ¦                ¦                          ¦               ¦лекарственными           ¦              ¦

¦     ¦биологических        ¦                ¦                          ¦               ¦препаратами              ¦              ¦

¦     ¦лекарственных        ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦препаратов           ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+              ¦

¦     ¦                     ¦      L40.5     ¦тяжелые распространенные  ¦терапевтическое¦лечение с применением    ¦              ¦

¦     ¦                     ¦                ¦формы псориаза            ¦лечение        ¦генно-инженерных         ¦              ¦

¦     ¦                     ¦                ¦артропатического,         ¦               ¦биологических            ¦              ¦

¦     ¦                     ¦                ¦резистентные к другим     ¦               ¦лекарственных препаратов ¦              ¦

¦     ¦                     ¦                ¦видам системной терапии   ¦               ¦                         ¦              ¦

+-----+---------------------+----------------+--------------------------+---------------+-------------------------+--------------+

¦                                                          НЕЙРОХИРУРГИЯ                                                         ¦

+-----T---------------------T----------------T--------------------------T---------------T-------------------------T--------------+

¦  7  ¦Микрохирургические   ¦  C71.0, C71.1, ¦внутримозговые            ¦хирургическое  ¦удаление опухоли с       ¦    130730    ¦

¦     ¦вмешательства с      ¦  C71.2, C71.3, ¦злокачественные           ¦лечение        ¦применением              ¦              ¦

¦     ¦использованием       ¦  C71.4, C79.3, ¦новообразования           ¦               ¦интраоперационной        ¦              ¦

¦     ¦операционного        ¦  D33.0, D43.0  ¦(первичные и вторичные) и ¦               ¦навигации                ¦              ¦

¦     ¦микроскопа,          ¦                ¦доброкачественные         ¦               ¦                         ¦              ¦

¦     ¦стереотаксической    ¦                ¦новообразования           ¦               ¦                         ¦              ¦

¦     ¦биопсии,             ¦                ¦функционально значимых    ¦               ¦                         ¦              ¦

¦     ¦интраоперационной    ¦                ¦зон больших полушарий     ¦               ¦                         ¦              ¦

¦     ¦навигации и          ¦                ¦головного мозга           ¦               ¦                         ¦              ¦

¦     ¦нейрофизиологического¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦мониторинга при      ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦внутримозговых       ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦новообразованиях     ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦головного мозга и    ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦каверномах           ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦функционально        ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦значимых зон         ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦головного мозга      ¦                ¦                          ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦                          ¦               +-------------------------+              ¦

¦     ¦                     ¦                ¦                          ¦               ¦удаление опухоли с       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦применением              ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦интраоперационного       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦ультразвукового          ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦сканирования             ¦              ¦

¦     ¦                     ¦                ¦                          ¦               +-------------------------+              ¦

¦     ¦                     ¦                ¦                          ¦               ¦удаление опухоли с       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦применением двух и более ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦методов лечения          ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦(интраоперационных       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦технологий)              ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+              ¦

¦     ¦                     ¦  C71.5, C79.3, ¦внутримозговые            ¦хирургическое  ¦удаление опухоли с       ¦              ¦

¦     ¦                     ¦  D33.0, D43.0  ¦злокачественные           ¦лечение        ¦применением              ¦              ¦

¦     ¦                     ¦                ¦(первичные и вторичные) и ¦               ¦интраоперационной        ¦              ¦

¦     ¦                     ¦                ¦доброкачественные         ¦               ¦навигации                ¦              ¦

¦     ¦                     ¦                ¦новообразования боковых и ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦III желудочков мозга      ¦               ¦                         ¦              ¦

¦     ¦                     ¦                ¦                          ¦               +-------------------------+              ¦

¦     ¦                     ¦                ¦                          ¦               ¦удаление опухоли с       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦применением              ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦интраоперационного       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦ультразвукового          ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦сканирования             ¦              ¦

¦     ¦                     ¦                ¦                          ¦               +-------------------------+              ¦

¦     ¦                     ¦                ¦                          ¦               ¦удаление опухоли с       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦применением двух и более ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦методов лечения          ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦(интраоперационных       ¦              ¦

¦     ¦                     ¦                ¦                          ¦               ¦технологий)              ¦              ¦

¦     ¦                     +----------------+--------------------------+---------------+-------------------------+              ¦

¦     ¦                     ¦  C71.6, C71.7, ¦внутримозговые            ¦хирургическое  ¦удаление опухоли с       ¦              ¦

¦     ¦                     ¦  C79.3, D33.1, ¦злокачественные           ¦лечение        ¦применением              ¦              ¦

¦     ¦                     ¦  D18.0, D43.1  ¦(первичные и вторичные) и ¦               ¦интраоперационной        ¦              ¦

¦     ¦                     ¦                ¦доброкачественные         ¦               ¦навигации                ¦              ¦